T cell lymphoproliferative disorders associated with anti-tumor necrosis factor alpha antibody therapy for ulcerative colitis: literature summary

The enhanced risk of development of lymphoproliferative disorders in patients with inflammatory bowel disease has been attributed to immunosuppressive/immunomodulatory therapies. Infliximab is a chimeric monoclonal immunoglobulin G1 antibody directed against tumor necrosis factor alpha (TNF-α) that...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, Lindsay A., Lim, Megan S.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2009
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2725290/
https://www.ncbi.nlm.nih.gov/pubmed/19669196
http://dx.doi.org/10.1007/s12308-009-0029-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2725290/
https://www.ncbi.nlm.nih.gov/pubmed/19669196
http://dx.doi.org/10.1007/s12308-009-0029-9

Ejemplares similares